TP53 and cancer: Among the evaluable patients, wild-type TP53 occurred in the cancers of 92.6% of patients in cohort A and mutant TP53 occurred in the cancers of 90% of patients in cohort B. Patient selection to include only wild-type TP53 disease may have yielded different results in cohort B, but likely not in cohort A. Studies to evaluate the activity of mitomycin-C in wild-type TP53, HPV-negative disease may be warranted.